Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Scientific Corp receives FDA approval for REBEL Platinum Chromium Coronary Stent System


Monday, 21 Jul 2014 04:30pm EDT 

Boston Scientific Corp:Receives FDA approval for REBEL Platinum Chromium Coronary Stent System, company's latest generation bare-metal stent for treatment of coronary artery disease (CAD).Bare-metal stents continue to play important role in treatment of CAD and represent a significant portion of the global stent market.Company announced CE Mark for Rebel Stent System in Feb.REBEL Stent System expands the Boston Scientific family of stents featuring its proprietary platinum chromium (PtCr) alloy and customized stent architecture design.REBEL Stent offers identical stent platform as Promus PREMIER Drug-Eluting Stent (DES) but without Everolimus drug.